DRUG · Unmapped registry intervention
XL309
Find medicine records ·
Find other trials using this name
Clinical trial
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
NCT05932862
Drugs and interventions used in this trial
2 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Mapped RxNorm record
Olaparib
Normalized identity: olaparibView linked drug · Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedA Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
Design: INTERVENTIONAL · Status: RECRUITING · Phase: PHASE1
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Advanced Solid Tumorunresolved
Interventions
XL309DRUG
OlaparibDRUG · verified · RxNorm: olaparib
Sponsors & collaborators
Exelixislead sponsor
Mapped research locations
HoustonTexas, United States2New YorkNew York, United States1San AntonioTexas, United States1NashvilleTennessee, United States1ClevelandOhio, United States1TampaFlorida, United States1JacksonvilleFlorida, United States1OrlandoFlorida, United States1Oklahoma CityOklahoma, United States1AustinTexas, United States1RochesterMinnesota, United States1Kansas CityMissouri, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT05932862 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.